SANO CHEMICALS, INC

BRYAN, TX · Biotech · Private

Novel antibiotic molecule targeting antibiotic-resistant pathogens

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · sanochemicals.com

Sector: Biotech
Headquarters: BRYAN, TX
Latest Form D: $350K, May 2024
Total capital: $5.2M

Federal grants: $4.2M; 8 awards · 2016–2024; Rank in peer group#222 of 514
Private capital raised: $1.1M; 2 Form D · last May 2024; 29 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Jul 2024Federal grantHealth and Human S · Phase II · Preclinical Development of Occidiofungin for Treatment of Oral and Dermal Candidiasis$300K
May 2024Private capital raisedForm D · SEC · 2nd filing$350K
Jan 2024Private capital raisedForm D · SEC · 1st filing$710K
Apr 2021Federal grantHealth and Human S · Phase II · Preclinical Development of OCF001 for Treatment of Yeast Infections$931K
Aug 2020Federal grantHealth and Human S · Phase I · A Novel Therapeutic Agent for the Treatment of Gram-positive Infections$233K
Apr 2020Federal grantHealth and Human S · Phase II · Preclinical Development of OCF001 for Treatment of Yeast Infections$966K
Mar 2019Federal grantHealth and Human S · Phase II · Preclinical Development of OCF001 for Treatment of Yeast Infections$983K

Show 3 earlier federal awards

Feb 2017Federal grantHealth and Human S · Phase I · Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin$234K
Feb 2017Federal grantHealth and Human S · Phase I · Lead Compound Discovery from Engineered Analogs of Occidiofungin$225K
Mar 2016Federal grantHealth and Human S · Phase I · Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin$295K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

94months

from SANO CHEMICALS, INC’s first federal award to its first private round.

First federal award · Mar 2016: Health and Human S · $295K
First Form D · Jan 2024: $710K · 1st Form D
Awards before first raise: 7 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#222 · top 43%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Frank AustinDirectorNamed in SEC Form D filings
James SmithExecutive OfficerNamed in SEC Form D filings
Shi-En LuDirectorNamed in SEC Form D filings
Stephen PruettDirectorNamed in SEC Form D filings
Timothy HieberyDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

AP NeomorphSimilar federal contract value in Biotech · null in contracts
NuvOx Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Hexamer Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
Truvitech, LLCSimilar federal contract value in Biotech · null in contracts
Telomir Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
IKAIKA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.